NOVEMBER/DECEMBER 2001

Vol 8, No 6 Supplement CME Pretest

This Supplement provides 1 hour of Category 1 Continuing Medical Education

Complimentary CME Credits

Healthcare professionals can earn 1 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this supplement or listening to the audiotape (if accessible), and successfully answering the questions in the posttest at the end of this supplement. Complete instructions are given on the posttest pages. Successfully answering 8 or more questions will earn 1 credit hours.

Educational Objectives

After completing this CME program, healthcare professionals will be expected to:

This program was planned in accordance with ACCME Essentials.

Release Date: November 1, 2001
Expiration Date: November 1, 2002

1. In advanced ovarian cancer, the use of aggressive debulking surgery followed by aggressive chemotherapy with the platinum complexes and the taxanes has increased patients’ expected survival to about:

a. 12-18 months
b. 2-3 years
c. 3-5 years
d. 6-8 years

2. A patient with primary platinum-refractory ovarian cancer (cancer that progresses during primary chemotherapy) would probably best be managed by:

a. second-look laparotomy
b. radiation therapy
c. chronic therapy (with chemotherapy)
d. palliative care

3. In patients with recurrent platinum-sensitive ovarian cancer, multiple doses of carboplatin may elevate the risk of cumulative myelosuppression and subsequently compromise the ability to give other useful but myelosuppressive drugs. Which one of the following drugs has dose-limiting toxicity other than myelosuppression?

a. liposomal doxorubicin
b. topotecan
c. gemcitabine
d. oral etoposide